Alternative asset manager Blackstone has completed the raising of USD 13.1 billion for its Asia private equity fund, exceeding its initial target and creating history by marking its largest such fundraise in the region.
The fundraising, apart from reflecting the growing and strong investor interest in Asia, also comes amid the geopolitical volatility created by the ongoing Iran war. Apart from Blackstone, Sweden-based EQT AB also benefitted from the positive investor environment, as it, in May 2026, raised USD 15.6 billion to create Asia’s largest private equity fund.
Blackstone, while targeting USD 10 billion for the fund named ”Blackstone Capital Partners Asia III,” ended up raising more than double the amount of its previous investment vehicle.
Asia has been gaining from the trend of global institutional and high-net-worth investors diversifying away from the United States due to high valuations, inflation risks, and overall geopolitical uncertainty. Markets like Japan and India, known for offering a steady pipeline of buyout and growth opportunities, have been a major focus area for global asset managers.
“Asia Pacific is the fastest-growing region in the world, presenting compelling opportunities to invest at scale behind our high-conviction themes and deliver for our investors,” said Joe Baratta, global head of Blackstone Private Equity Strategies.
Bain Capital recently raised about USD 10.5 billion in its sixth pan-Asia buyout fund, while KKR & Co., which, in 2021, raised the record amount of USD 15 billion for its pan-Asia fund, is now reportedly looking to collect USD 15 billion for its next such vehicle.
Talking about Blackstone’s Asia-related activities, since 2024, the alternative asset management giant has invested more than USD 7 billion in 12 deals in India and Japan, including companies such as Indian AI cloud platform Neysa and Japan’s engineering services provider TechnoPro. The firm also exited 15 companies during the period, including through listings of the International Gemological Institute and Aadhar Housing Finance, along with Japan’s Alinamin Pharmaceutical.